keyword
MENU ▼
Read by QxMD icon Read
search

Azithromycin asthma

keyword
https://www.readbyqxmd.com/read/28118241/management-of-preschool-recurrent-wheezing-and-asthma-a-phenotype-based-approach
#1
Avraham Beigelman, Leonard B Bacharier
PURPOSE OF REVIEW: The purpose of this review is to summarize the recent evidence on the management of preschool children with wheezing and asthma, and to propose a phenotype-based approach to the management of these children. RECENT FINDINGS: Recent studies have begun to identify populations of preschool children that are likely to benefit from inhaled corticosteroids (ICS) therapy and defined ICS regimens: daily ICS in preschool children with persistent asthma, and pre-emptive high-dose intermittent ICS among preschool children with intermittent disease reduce the risk of exacerbation...
January 21, 2017: Current Opinion in Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28116959/immunomodulatory-indications-of-azithromycin-in-respiratory-disease-a-concise-review-for-the-clinician
#2
Cassondra L Cramer, Allie Patterson, Abdulrazak Alchakaki, Ayman O Soubani
Azithromycin has a well-characterized bacteriostatic activity. However, it also has a robust immunomodulatory effect that has proven beneficial in a variety of chronic illnesses. This effect results in decreased production of pro-inflammatory cytokines in the acute phase and promotes resolution of chronic inflammation in the later phases. Specifically, azithromycin has direct activity on airway epithelial cells to maintain their function and reduce mucus secretion. These characteristics have resulted in the use of azithromycin in the management of a variety of chronic lung diseases including chronic obstructive pulmonary disease, cystic fibrosis (CF), non-CF bronchiectasis, bronchiolitis obliterans syndrome, diffuse panbronchiolitis, and asthma...
February 1, 2017: Postgraduate Medicine
https://www.readbyqxmd.com/read/28051240/clinical-effect-of-treating-secondary-asthma-attacks-of-children-mycoplasma-pneumoniae-with-combined-therapy-of-montelukast-and-azithromycin
#3
L Gong, L Xu, M Diao, F Guo, F-F Bian, J Min, R Liu, C-L Zhang
OBJECTIVE: To discuss the clinical effects of treating secondary asthma attacks of children Mycoplasma pneumoniae with combined therapy of montelukast and azithromycin. PATIENTS AND METHODS: 96 children patients diagnosed with secondary asthma attacks of Mycoplasma pneumonia were enrolled in this study. They were randomly divided into two groups: the control group (n=49) and the observation group (n=47). Patients in the control group received combined therapy using azithromycin and bronchodilators or glucocorticoid, and patients in the observation group received a combined therapy of montelukast, azithromycin and bronchodilators or glucocorticoid...
December 2016: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/27916734/azithromycin-ameliorates-airway-remodeling-via-inhibiting-airway-epithelium-apoptosis
#4
Yuanqi Liu, Yue Pu, Diandian Li, Liming Zhou, Lihong Wan
AIMS: Azithromycin can benefit treating allergic airway inflammation and remodeling. In the present study, we hypothesized that azithromycin alleviated airway epithelium injury through inhibiting airway epithelium apoptosis via down regulation of caspase-3 and Bax/Bcl2 ratio in vivo and in vitro. MAIN METHODS: Ovalbumin induced rat asthma model and TGF-β1-induced BEAS-2B cell apoptosis model were established, respectively. In vivo experiments, airway epithelium was stained with hematoxylin and eosin (HE) and periodic acid-Schiff (PAS) to histologically evaluate the airway inflammation and remodeling...
February 1, 2017: Life Sciences
https://www.readbyqxmd.com/read/27908909/dtb-select-12-december-2016
#5
(no author information available yet)
Azithromycin of no benefit for asthma attacks ● Risk of heart failure with NSAIDs ● Bisphosphonates and steroid-induced osteoporosis ● Triple therapy for moderate-to-severe COPD: marginal benefits ● Much data on adverse events remains unpublished ● Rising placebo response rates in antidepressant trials a 'myth' ● Prenatal fetal RhD testing recommended.
December 2016: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/27832694/long-term-follow-up-of-sulfur-mustard-related-bronchiolitis-obliterans-treatment
#6
Hamidreza Abtahi, Soheil Peiman, Morteza Foroumandi, Enayat Safavi
Bronchiolitis obliterans (BO) is the most remarkable pulmonary sequels of war-related sulfur mustard inhalation. There is little if any data about long-term efficacy of associated BO treatment. Five years spirometric records of three groups of patients with obstructive pulmonary diseases (asthma, COPD, BO) and documented sulfur mustard inhalation were evaluated. The BO patients were treated with inhaled Seretide 125-250/25 (2 puffs BID), azithromycin (250 mg, three times/week) and N-acetylcysteine (1200-1800/day)...
September 2016: Acta Medica Iranica
https://www.readbyqxmd.com/read/27613392/pharmacological-strategies-to-reduce-exacerbation-risk-in-copd-a-narrative-review
#7
REVIEW
Marc Miravitlles, Anthony D'Urzo, Dave Singh, Vladimir Koblizek
Identifying patients at risk of exacerbations and managing them appropriately to reduce this risk represents an important clinical challenge. Numerous treatments have been assessed for the prevention of exacerbations and their efficacy may differ by patient phenotype. Given their centrality in the treatment of COPD, there is strong rationale for maximizing bronchodilation as an initial strategy to reduce exacerbation risk irrespective of patient phenotype. Therefore, in patients assessed as frequent exacerbators (>1 exacerbation/year) we propose initial bronchodilator treatment with a long-acting muscarinic antagonist (LAMA)/ long-acting β2-agonist (LABA)...
September 10, 2016: Respiratory Research
https://www.readbyqxmd.com/read/27494903/identification-of-novel-macrolides-with-antibacterial-anti-inflammatory-and-type-i-and-iii-ifn-augmenting-activity-in-airway-epithelium
#8
James D Porter, Jennifer Watson, Lee R Roberts, Simren K Gill, Helen Groves, Jaideep Dhariwal, Mark H Almond, Ernie Wong, Ross P Walton, Lyn H Jones, John Tregoning, Iain Kilty, Sebastian L Johnston, Michael R Edwards
BACKGROUND: Exacerbations of asthma and COPD are triggered by rhinoviruses. Uncontrolled inflammatory pathways, pathogenic bacterial burden and impaired antiviral immunity are thought to be important factors in disease severity and duration. Macrolides including azithromycin are often used to treat the above diseases, but exhibit variable levels of efficacy. Inhaled corticosteroids are also readily used in treatment, but may lack specificity. Ideally, new treatment alternatives should suppress unwanted inflammation, but spare beneficial antiviral immunity...
October 2016: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/27465667/azithromycin-for-the-treatment-of-eosinophilic-nasal-polyposis-clinical-and-histologic-analysis
#9
Isamara Simas de Oliveira, Paulo Fernando Tormin Borges Crosara, Geovanni Dantas Cassali, Diego Carlos Dos Reis, Danilo Santana Rodrigues, Flavio Barbosa Nunes, Roberto Eustáquio Santos Guimarães
INTRODUCTION: Macrolides used as immunomodulators are a promising tool for chronic inflammatory airway diseases. Eosinophilic nasal polyposis (ENP) is still considered a disease that is difficult to control with the currently standardized treatments. OBJECTIVES: To evaluate prolonged treatment with low-dose azithromycin for ENP based on clinical and histopathologic variables. METHODS: The present investigation was a self-paired case study of 33 patients with ENP...
January 2016: Allergy & Rhinology
https://www.readbyqxmd.com/read/27458539/macrolides-for-acute-wheezing-episodes-in-preschool-children
#10
Hengameh H Raissy, Kathryn Blake
The National Asthma Education and Prevention Program's Expert Panel Report 3, Guidelines for the Diagnosis and Management of Asthma does not recommend antibiotics for the management of acute episodes of asthma exacerbation. Macrolides seem to have some potential effect beyond or in addition to their antibacterial effect. It has been reported that macrolides may potentially benefit patients with chronic inflammatory airway diseases due to their antibacterial, antiviral, and/or anti-inflammatory effects. This review presents recent data on use of azithromycin in prevention and management of acute exacerbation of respiratory symptoms in infants and young children...
June 1, 2016: Pediatric Allergy, Immunology, and Pulmonology
https://www.readbyqxmd.com/read/27264915/medication-palatability-affects-physician-prescribing-preferences-for-common-pediatric-conditions
#11
Hans Bradshaw, Michael J Mitchell, Christopher J Edwards, Uwe Stolz, Oday Naser, Amanda Peck, Asad E Patanwala
OBJECTIVES: The objective of this study was to determine if physicians would alter their prescribing preferences after sampling liquid formulations of medications for common pediatric diagnoses. METHODS: This was a prospective interventional before/after study conducted at an academic medical center in the United States. The participants of interest included emergency, family medicine, and pediatric physicians. Participants initially completed a brief survey for their primary oral liquid medication of choice for the treatment of selected disease states...
November 2016: Academic Emergency Medicine: Official Journal of the Society for Academic Emergency Medicine
https://www.readbyqxmd.com/read/27246785/azithromycin-differentially-affects-the-il-13-induced-expression-profile-in-human-bronchial-epithelial-cells
#12
Tinne C J Mertens, Pieter S Hiemstra, Christian Taube
The T helper 2 (Th2) cytokine interleukin(IL)-13 is a central regulator in goblet cell metaplasia and induces the recently described Th2 gene signature consisting of periostin (POSTN), chloride channel regulator 1 (CLCA1) and serpin B2 (SERPINB2) in airway epithelial cells. This Th2 gene signature has been proposed as a biomarker to classify asthma into Th2-high and Th2-low phenotypes. Clinical studies have shown that the macrolide antibiotic azithromycin reduced clinical symptoms in neutrophilic asthma, but not in the classical Th2-mediated asthma despite the ability of azithromycin to reduce IL-13-induced mucus production...
August 2016: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27220906/linx%C3%A2-a-novel-treatment-for-patients-with-refractory-asthma-complicated-by-gastroesophageal-reflux-disease-a-case-report
#13
Narin Sriratanaviriyakul, Celeste Kivler, Tamas J Vidovszky, Ken Y Yoneda, Nicholas J Kenyon, Susan Murin, Samuel Louie
BACKGROUND: Gastroesophageal reflux disease is one of the most common comorbidities in patients with asthma. Gastroesophageal reflux disease can be linked to difficult-to-control asthma. Current management includes gastric acid suppression therapy and surgical antireflux procedures. The LINX® procedure is a novel surgical treatment for patients with gastroesophageal reflux disease refractory to medical therapy. To the best of our knowledge, we report the first case of successful treatment of refractory asthma secondary to gastroesophageal reflux disease using the LINX® procedure...
May 24, 2016: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/27029691/oral-azithromycin-for-acute-episodic-airway-symptoms-in-young-children-pediatric-asthma-experts-viewpoint
#14
Puneet Sahi, Virendra Kumar
No abstract text is available yet for this article.
March 2016: Indian Pediatrics
https://www.readbyqxmd.com/read/26836927/the-effects-of-azithromycin-in-treatment-resistant-cough-a-randomized-double-blind-placebo-controlled-trial
#15
RANDOMIZED CONTROLLED TRIAL
David Hodgson, John Anderson, Catherine Reynolds, Janet Oborne, Garry Meakin, Helen Bailey, Dominick Shaw, Kevin Mortimer, Tim Harrison
BACKGROUND: Chronic cough is a common clinical problem worldwide. Although many patients have underlying precipitating conditions such as asthma, gastroesophageal reflux, or rhinitis, many remain symptomatic despite treating these conditions. New approaches are needed for the treatment of this group of patients. METHODS: We conducted a randomized, double-blind, placebo-controlled trial to determine whether 250 g of azithromycin three times a week for 8 weeks would affect the Leicester Cough Questionnaire (LCQ) score in 44 patients with treatment-resistant cough...
April 2016: Chest
https://www.readbyqxmd.com/read/26778828/long-term-azithromycin-ameliorates-not-only-airway-inflammation-but-also-remodeling-in-a-murine-model-of-chronic-asthma
#16
Ji Young Kang, Mi Ran Jo, Hyeon Hui Kang, Sung Kyoung Kim, Myoung Sook Kim, Yong Hyun Kim, Seok Chan Kim, Soon Seog Kwon, Sook Young Lee, Jin Woo Kim
OBJECTIVES: We investigated the effect of long-term treatment with azithromycin on the pathogenesis of chronic asthma with airway remodeling. METHODS: Six-week-old-BALB/c mice were sensitized with ovalbumin (OVA) combined with lipopolysaccharide (LPS) for 1 month, then challenged with OVA for 3 months. Azithromycin at 75 mg/kg was administered via oral gavage five times a week during the challenge period. Inflammatory cells, T helper 2 cytokines in bronchoalveolar lavage fluid (BAL) fluid, and airway hyperresponsiveness (AHR) were measured...
February 2016: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/26704020/azithromycin-for-episodes-with-asthma-like-symptoms-in-young-children-aged-1-3-years-a-randomised-double-blind-placebo-controlled-trial
#17
RANDOMIZED CONTROLLED TRIAL
Jakob Stokholm, Bo L Chawes, Nadja H Vissing, Elín Bjarnadóttir, Tine M Pedersen, Rebecca K Vinding, Ann-Marie M Schoos, Helene M Wolsk, Sunna Thorsteinsdóttir, Henrik W Hallas, Lambang Arianto, Susanne Schjørring, Karen A Krogfelt, Thea K Fischer, Christian B Pipper, Klaus Bønnelykke, Hans Bisgaard
BACKGROUND: Bacteria and viruses are equally associated with the risk of acute episodes of asthma-like symptoms in young children, suggesting antibiotics as a potential treatment for such episodes. We aimed to assess the effect of azithromycin on the duration of respiratory episodes in young children with recurrent asthma-like symptoms, hypothesising that it reduces the duration of the symptomatic period. METHODS: In this randomised, double-blind, placebo-controlled trial, we recruited children aged 1-3 years, who were diagnosed with recurrent asthma-like symptoms from the Copenhagen Prospective Studies on Asthma in Childhood 2010 cohort; a birth cohort consisting of the general Danish population of Zealand, including Copenhagen...
January 2016: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/26601998/evaluation-of-the-improvement-of-quality-of-life-with-azithromycin-in-the-treatment-of-eosinophilic-nasal-polyposis
#18
Isamara Simas de Oliveira, Paulo Fernando Tormin Borges Crosara, Geovanni Dantas Cassali, Diego Carlos dos Reis, Camilo Brandão de Resende, Flavio Barbosa Nunes, Roberto Eustáquio Santos Guimarães
INTRODUCTION: The Sino-Nasal Outcome Test 22 (SNOT-22) is an important tool in assessing the quality of life (QoL) of patients with chronic rhinosinusitis with a validated version in Brazil. The eosinophilic nasal polyposis (ENP) represents most of the cases of nasal polyposis (85-90%) and belongs to the group of chronic rhinosinusitis. It is a chronic inflammatory disease that impacts the QoL of patients, not only causing localized symptoms, but also resulting in a general malaise. The standard treatments (corticosteroids and nasal endoscopic surgery) lead to partial control of symptoms, but relapses are frequent...
March 2016: Brazilian Journal of Otorhinolaryngology
https://www.readbyqxmd.com/read/26441370/past-present-and-future-of-macrolide-therapy-for-chronic-rhinosinusitis-in-japan
#19
REVIEW
Takeshi Shimizu, Harumi Suzaki
In 1984, the effectiveness of low-dose, long-term erythromycin treatment (macrolide therapy) for diffuse panbronchiolitis (DPB) was first reported in Japan. The 5-year survival rate for DPB improved from 62.9 to 91.4% after implementation of macrolide therapy. The usefulness of this treatment has since been demonstrated in patients with other chronic airway diseases, such as chronic bronchitis, cystic fibrosis, bronchiectasis, bronchial asthma, and chronic rhinosinusitis (CRS). The new 14-membered macrolides clarithromycin and roxithromycin and the 15-membered macrolide azithromycin are also effective for treating these inflammatory diseases...
April 2016: Auris, Nasus, Larynx
https://www.readbyqxmd.com/read/26152605/azithromycin-inhibits-il-1-secretion-and-non-canonical-inflammasome-activation
#20
Guido A Gualdoni, Tilman Lingscheid, Klaus G Schmetterer, Annika Hennig, Peter Steinberger, Gerhard J Zlabinger
Deregulation of inflammasome activation was recently identified to be involved in the pathogenesis of various inflammatory diseases. Although macrolide antibiotics display well described immunomodulatory properties, presumably involved in their clinical effects, their impact on inflammasome activation has not been investigated. We compared the influence of macrolides on cytokine induction in human monocytes. The role of intracellular azithromycin-accumulation was examined by interference with Ca(++)-dependent uptake...
2015: Scientific Reports
keyword
keyword
97017
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"